Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Chondrosarcoma Epidemiology Forecast

DelveInsight’s ‘Chondrosarcoma - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Chondrosarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Chondrosarcoma: Understanding

The DelveInsight’s Chondrosarcoma epidemiology report gives a thorough understanding of Chondrosarcoma by including details such as disease classification, pathophysiology, biomarkers and diagnosis. It also provides treatment algorithms and treatment guidelines for Chondrosarcoma in the US and Europe. Moreover, the report covers detailed information on the Chondrosarcoma epidemiology scenario in seven major countries (US, EU5, and Japan).


Epidemiology Perspective by DelveInsight:

This section encompassing Chondrosarcoma epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Chondrosarcoma epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.


Detailed Epidemiology Segmentation:

The Chondrosarcoma epidemiology covered in the report provides historical as well as forecasted Chondrosarcoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.


The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report:

  • The Chondrosarcoma report covers a detailed overview explaining its etiology, pathophysiology classification, diagnosis and treatment patterns
  • The Chondrosarcoma report and model provide an overview of the global trends of Chondrosarcoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Chondrosarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Chondrosarcoma.
  • The report provides the segmentation of the Chondrosarcoma epidemiology


Report Highlights:

  • 11-year Forecast of Chondrosarcoma Epidemiology
  • 7MM Coverage
  • Incidence of chondrosarcoma,
  • Type-specific cases of chondrosarcoma,
  • Type-specific cases of primary chondrosarcoma 
  • Grade-specific cases of chondrosarcoma


KOL Views:

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered:

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Chondrosarcoma?
  • What are the key findings pertaining to the Chondrosarcoma epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of patients of Chondrosarcoma across the 7MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
  • What is the disease risk, burden, and unmet needs of Chondrosarcoma?
  • What are the currently available treatments of Chondrosarcoma?


Reasons to buy:

The Chondrosarcoma Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Chondrosarcoma market.
  • Quantify patient populations in the global Chondrosarcoma market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chondrosarcoma therapeutics in each of the markets covered
  • Understand the magnitude of Chondrosarcoma population by its epidemiology
  • The Chondrosarcoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments:

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

 

1 Key Insights

2 Executive Summary of Chondrosarcoma

3 SWOT Analysis for Chondrosarcoma

4 Chondrosarcoma Market Overview at a Glance

4.1 Market Share (%) Distribution of Chondrosarcoma In 2017

4.2 Market Share (%) Distribution of Chondrosarcoma In 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Histological grading

5.3 Classification and characteristics of Chondrosarcoma

5.3.1 Conventional chondrosarcoma

5.3.2 Non-conventional chondrosarcoma

5.4 Signaling pathways involved in chondrosarcoma development

5.5 Biomarkers

5.6 Diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Incident Patient Population of Chondrosarcoma

6.3 Assumptions and Rationale

6.4 The United States

6.4.1 Incident Population of Chondrosarcoma in the United States

6.4.2 Type-specific cases of Chondrosarcoma in the United States

6.4.3 Type-specific cases of Primary Chondrosarcoma in the United States

6.4.4 Grade-specific cases of Chondrosarcoma in the United States

6.5 EU5 Countries

6.5.1 Germany

6.5.1.1 Incident Population of Chondrosarcoma in Germany

6.5.1.2 Type-specific cases of Chondrosarcoma in Germany

6.5.1.3 Type-specific cases of Primary Chondrosarcoma in Germany

6.5.1.4 Grade-specific cases of Chondrosarcoma in Germany

6.5.2 France

6.5.2.1 Incident Population of Chondrosarcoma in France

6.5.2.2 Type-specific cases of Chondrosarcoma in France

6.5.2.3 Type-specific cases of Primary Chondrosarcoma in France

6.5.2.4 Grade-specific cases of Chondrosarcoma in France

6.5.3 Italy

6.5.3.1 Incident Population of Chondrosarcoma in Italy

6.5.3.2 Type-specific cases of Chondrosarcoma in Italy

6.5.3.3 Type-specific cases of Primary Chondrosarcoma in Italy

6.5.3.4 Grade-specific cases of Chondrosarcoma in Italy

6.5.4 Spain

6.5.4.1 Incident Population of Chondrosarcoma in Spain

6.5.4.2 Type-specific cases of Chondrosarcoma in Spain

6.5.4.3 Type-specific cases of Primary Chondrosarcoma in Spain

6.5.4.4 Grade-specific cases of Chondrosarcoma in Spain

6.5.5 The United Kingdom

6.5.5.1 Incident Population of Chondrosarcoma in the United Kingdom

6.5.5.2 Type-specific cases of Chondrosarcoma in the United Kingdom

6.5.5.3 Type-specific cases of Primary Chondrosarcoma in the United Kingdom

6.5.5.4 Grade-specific cases of Chondrosarcoma in the United Kingdom

6.6 Japan

6.6.1 Incident Population of Chondrosarcoma in Japan

6.6.2 Type-specific cases of Chondrosarcoma in Japan

6.6.3 Type-specific cases of Primary Chondrosarcoma in Japan

6.6.4 Grade-specific cases of Chondrosarcoma in Japan

7 Treatment and Management

7.1 Treatment Guidelines

7.1.1 NCCN Guidelines

7.1.2 ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

8 Case Study

8.1 Intraspinal Mesenchymal Chondrosarcoma: Report of a Pediatric Case and Literature Review

9 Patient Journey

10 Unmet Needs

11 Appendix

11.1 Report Methodology

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight

List of Table

Table 1: Summary of Chondrosarcoma Market, Epidemiology, and Key Events (2017–2030)

Table 2:Total Incident Patient Population of Chondrosarcoma in the 7MM (2017–2030)

Table 3: Incident Population of Chondrosarcoma in the United States (2017–2030)

Table 4: Type-specific cases of Chondrosarcoma in the United States (2017–2030)

Table 5: Type-specific cases of Primary Chondrosarcoma in the United States (2017–2030)

Table 6: Grade-specific cases of Chondrosarcoma in the United States (2017–2030)

Table 7: Incident Population of Chondrosarcoma in Germany (2017–2030)

Table 8: Type-specific cases of Chondrosarcoma in Germany (2017–2030)

Table 9: Type-specific cases of Primary Chondrosarcoma in Germany (2017–2030)

Table 10: Grade-specific cases of Chondrosarcoma in Germany (2017–2030)

Table 11: Incident Population of Chondrosarcoma in France (2017–2030)

Table 12: Type-specific cases of Chondrosarcoma in France (2017–2030)

Table 13: Type-specific cases of Primary Chondrosarcoma in France (2017–2030)

Table 14: Grade-specific cases of Chondrosarcoma in France (2017–2030)

Table 15: Incident Population of Chondrosarcoma in Italy (2017–2030)

Table 16: Type-specific cases of Chondrosarcoma in Italy (2017–2030)

Table 17: Type-specific cases of Primary Chondrosarcoma in Italy (2017–2030)

Table 18: Grade-specific cases of Chondrosarcoma in Italy (2017–2030)

Table 19: Incident Population of Chondrosarcoma in Spain (2017–2030)

Table 20: Type-specific cases of Chondrosarcoma in Spain (2017–2030)

Table 21: Type-specific cases of Primary Chondrosarcoma in Spain (2017–2030)

Table 22: Grade-specific cases of Chondrosarcoma in Spain (2017–2030)

Table 23: Incident Population of Chondrosarcoma in the United Kingdom (2017–2030)

Table 24: Type-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)

Table 25: Type-specific cases of Primary Chondrosarcoma in the United Kingdom (2017–2030)

Table 26: Grade-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)

Table 27: Incident Population of Chondrosarcoma in Japan (2017–2030)

Table 28: Type-specific cases of Chondrosarcoma in Japan (2017–2030)

Table 29: Type-specific cases of Primary Chondrosarcoma in Japan (2017–2030)

Table 30: Grade-specific cases of Chondrosarcoma in Japan (2017–2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: The involved molecular pathways responsible for CH development

Figure 3: Chondrosarcoma signaling

Figure 4: The IHH/PTHrP signaling pathway

Figure 5: Incident Cases of Chondrosarcoma in the 7MM (2017–2030)

Figure 6: Incident Population of Chondrosarcoma in the United States (2017–2030)

Figure 7: Type-specific cases of Chondrosarcoma in the United States (2017–2030)

Figure 8: Type-specific cases of Primary Chondrosarcoma in the United States (2017–2030)

Figure 9: Grade-specific cases of Chondrosarcoma in the United States (2017–2030)

Figure 10: Incident Population of Chondrosarcoma in Germany (2017–2030)

Figure 11: Type-specific cases of Chondrosarcoma in Germany (2017–2030)

Figure 12: Type-specific cases of Primary Chondrosarcoma in Germany (2017–2030)

Figure 13: Grade-specific cases of Chondrosarcoma in Germany (2017–2030)

Figure 14: Incident Population of Chondrosarcoma in France (2017–2030)

Figure 15: Type-specific cases of Chondrosarcoma in France (2017–2030)

Figure 16: Type-specific cases of Primary Chondrosarcoma in France (2017–2030)

Figure 17: Grade-specific cases of Chondrosarcoma in France (2017–2030)

Figure 18: Incident Population of Chondrosarcoma in Italy (2017–2030)

Figure 19: Type-specific cases of Chondrosarcoma in Italy (2017–2030)

Figure 20: Type-specific cases of Primary Chondrosarcoma in Italy (2017–2030)

Figure 21: Grade-specific cases of Chondrosarcoma in Italy (2017–2030)

Figure 22: Incident Population of Chondrosarcoma in Spain (2017–2030)

Figure 23: Type-specific cases of Chondrosarcoma in Spain (2017–2030)

Figure 24: Type-specific cases of Primary Chondrosarcoma in Spain (2017–2030)

Figure 25: Grade-specific cases of Chondrosarcoma in Spain (2017–2030)

Figure 26: Incident Population of Chondrosarcoma in the United Kingdom (2017–2030)

Figure 27: Type-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)

Figure 28: Type-specific cases of Primary Chondrosarcoma in the United Kingdom (2017–2030)

Figure 29: Grade-specific cases of Chondrosarcoma in the United Kingdom (2017–2030)

Figure 30: Incident Population of Chondrosarcoma in Japan (2017–2030)

Figure 31: Type-specific cases of Chondrosarcoma in Japan (2017–2030)

Figure 32: Type-specific cases of Primary Chondrosarcoma in Japan (2017–2030)

Figure 33: Grade-specific cases of Chondrosarcoma in Japan (2017–2030)

Forward to Friend

Need A Quote